Cell-Free DNA Methylation Predicts Chemo Benefit in Bladder Cancer
Methylation patterns in cfDNA from blood samples can help predict which patients with a type of bladder cancer may benefit from chemotherapy.
Category: Unknown Origin & Other Cancer Types
Unknown Origin & Other Cancer Types
Latest
Unknown Origin & Other Cancer Types
Latest
Forgetting the Lab Has Consequences
Learn how CLP's editor discovered firsthand how clinical laboratories and laboratorians are being taken for granted.
Unknown Origin & Other Cancer Types
Latest
Genetic Testing Could Reduce Rare Pediatric Cancer Deaths by Half
Genetic testing of the siblings of newborns with cancer genes could reduce rare pediatric cancer deaths by about 50%, an NIH-funded analysis suggests.
Viruses May Impact Health Long After infection
Cells undergo long-term changes after viral infection, pointing to why hepatitis C patients are susceptible to liver cancer.
Read More
FDA Grants Marketing Authorization For Siemens ELF Test
Siemens Healthineers’ Enhanced Liver Fibrosis (ELF) Test was granted marketing authorization under the De Novo review pathway.
Read More
Oncoguard Liver Liquid Biopsy Test Shows Potential For Better Early-stage Cancer Detection
Exact Sciences Corp. announced that the performance of its Oncoguard Liver liquid biopsy test is...
Read More
More Genetic Markers for Inherited Testicular Cancer Identified
A meta-analysis of nearly 200,000 men revealed 22 new genetic locations that could be susceptible to inherited TGCT.
Read More
Arquer Diagnostics’ ADXBLADDER Undergoes U.S. Clinical Trials
ADXBLADDER, a urinary biomarker test for bladder cancer, is currently undergoing clinical trials in the U.S.
Read More
AnchorDx UriFind Bladder Cancer Test Gets FDA Breakthrough Device Designation
The FDA awarded AnchorDx a Breakthrough Device Designation for UriFind, an early detection test for bladder cancer based on urine DNA methylation detection.
Read More
Blood Test May Predict Response in Metastatic HPV-Positive Throat Cancer
The test being developed could signal whether metastatic HPV-positive throat cancer treatment is working months earlier than standard imaging scans, allowing doctors to try alternatives sooner, initial results show.
Read More
Birmingham University, Nonacus Partner to Develop Urine Test for Bladder Cancer
The urine test, which is expected to be available by mid-2022, will use highly sensitive liquid biopsy technology developed by Nonacus and a panel of biomarkers validated by Birmingham University researchers to diagnose bladder cancer.
Read More
New Saliva Test Detects Head and Neck Cancer
A new clinically-validated saliva test has been shown to detect HPV-associated head and neck cancer with high accuracy.
Read More
Multiple Myeloma Study Completes Enrollment, Method Development
The study aims to use a combination of blood-based testing, imaging, bone marrow sampling, and clinical questionnaires to improve our basic understanding of monoclonal gammopathy of undetermined significance, which precedes multiple myeloma.
Read More
Novel Urine Screening Test Can Detect New and Recurrent Bladder Cancer
A study found a new urine screening test using a novel K17 cancer biomarker can detect new bladder cancer in patients with blood in the urine.
Read More
Urine Protein Biomarkers May Have Diagnostic Potential
Researchers have identified urine protein biomarkers of bladder cancer. ELISA validation was used to validate the top four biomarkers.
Read More
Ovarian Cancer Screening Did Not Reduce Deaths
A large-scale randomized trial of annual screening for ovarian cancer did not succeed in reducing deaths from the disease, despite one of the screening methods tested detecting cancers earlier.
Read More
Veracyte to Acquire Decipher Biosciences
Decipher’s comprehensive portfolio of tests in urologic cancers leverage whole transcriptome analysis and proprietary machine learning algorithms to improve patient decision-making.
Read More
Qlucore Awarded Grant to Aid Clinical Diagnostics of Cancer
The grant will allow Qlucore to expand Qlucore Diagnostics software with a focus on RNA-profiling of glioma and acute leukemia.
Read More